Patents by Inventor Vijay Kuchroo
Vijay Kuchroo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11209440Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.Type: GrantFiled: August 24, 2016Date of Patent: December 28, 2021Inventors: Vijay Kuchroo, Aviv Regev, Jellert Gaublomme, Youjin Lee, Alexander K. Shalek, Chao Wang, Nir Yosef, Hongkun Park
-
Patent number: 10822587Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.Type: GrantFiled: August 27, 2015Date of Patent: November 3, 2020Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.Inventors: Aviv Regev, Vijay Kuchroo, Hongkun Park, Nir Yosef, Alexander K. Shalek, Jellert Gaublomme, Nicole C. Joller, Chuan Wu, Ana Carrizosa Anderson
-
Publication number: 20190040154Abstract: Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fg12 and/or IL-33 are also described herein.Type: ApplicationFiled: October 2, 2018Publication date: February 7, 2019Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Vijay Kuchroo, Nicole Joller, Ana C. Anderson, Patrick Burkett
-
Publication number: 20170165325Abstract: Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.Type: ApplicationFiled: February 24, 2017Publication date: June 15, 2017Inventors: Arlene Sharpe, Loise M. Francisco, Vijay Kuchroo
-
Publication number: 20170107300Abstract: Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fgl2 and/or IL-33 are also described herein.Type: ApplicationFiled: March 20, 2015Publication date: April 20, 2017Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Vijay KUCHROO, Nicole JOLLER, Ana C. ANDERSON, Patrick BURKETT
-
Patent number: 9580684Abstract: Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.Type: GrantFiled: September 1, 2011Date of Patent: February 28, 2017Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.Inventors: Arlene Sharpe, Loise M. Francisco, Vijay Kuchroo
-
Publication number: 20160377631Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.Type: ApplicationFiled: August 24, 2016Publication date: December 29, 2016Inventors: Vijay Kuchroo, Aviv REGEV, Jellert GAUBLOMME, Youjin LEE, Alexander K. SHALEK, Chao WANG, Nir YOSEF, Hongkun PARK
-
Publication number: 20150361396Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.Type: ApplicationFiled: August 27, 2015Publication date: December 17, 2015Inventors: Aviv Regev, Vijay Kuchroo, Hongkun Park, Nir Yosef, Alexander K. Shalek, Jellert Gaublomme, Nicole C. Joller, Chuan Wu, Ana Carrizosa Anderson
-
Publication number: 20120076805Abstract: Methods and compositions for generating and maintaining induced regulatory T cells (iTregs) are provided. Methods and compositions for treating an autoimmune disorder, organ transplant rejection, graft versus host disease or allergic or hypersensitivity and inflammation are also provided.Type: ApplicationFiled: September 1, 2011Publication date: March 29, 2012Applicants: The Brigham and Women's Hospital, Inc., Presidents and Fellows of Harvard CollegeInventors: Arlene Sharpe, Loise M. Francisco, Vijay Kuchroo
-
Patent number: 7553939Abstract: A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.Type: GrantFiled: July 1, 2002Date of Patent: June 30, 2009Assignees: The Board of Trustees of the Leland Stanford Junior University, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.Inventors: Jennifer Jones McIntire, Rosemarie Dekruyff, Dale T. Umetsu, Gordon J. Freeman, Vijay Kuchroo
-
Publication number: 20090110687Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: ApplicationFiled: November 24, 2008Publication date: April 30, 2009Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Vijay Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Patent number: 7470428Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: GrantFiled: January 30, 2003Date of Patent: December 30, 2008Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer InstituteInventors: Vijay Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Publication number: 20050261224Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.Type: ApplicationFiled: March 14, 2005Publication date: November 24, 2005Applicant: Brigham and Women's HospitalInventors: Vijay Kuchroo, Sumone Chakravarti, Terry Strom, Xin Zheng, Jennifer Meyers
-
Publication number: 20050191721Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.Type: ApplicationFiled: October 4, 2004Publication date: September 1, 2005Applicants: Brigham and Women's Hospital, Beth Israel Deaconess Medical CenterInventors: Vijay Kuchroo, Terry Strom, Eugene Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Zheng, Alberto Sanchez-Fueyo
-
Publication number: 20050070459Abstract: The invention generally relates to improved methods for treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease.Type: ApplicationFiled: November 26, 2002Publication date: March 31, 2005Applicants: Brigham and Women"s Hospital, Trustees of Tufts CollegeInventors: William Bachovchin, Vijay Kuchroo
-
Publication number: 20030166531Abstract: The present invention provides methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods for treating a subject having a disorder that would benefit from down regulation of an immune response comprising administering an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention also provides methods for identifying compounds capable of modulating the interaction of CTLA4 and PP2AA.Type: ApplicationFiled: February 15, 2002Publication date: September 4, 2003Applicant: Genetics Institute, Inc.Inventors: Joaquin Madrenas, Mary Collins, Beatriz Carreno, Vijay Kuchroo
-
Publication number: 20030124114Abstract: A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.Type: ApplicationFiled: July 1, 2002Publication date: July 3, 2003Inventors: Jennifer Jones McIntire, Rosemarie Dekruyff, Dale T. Umetsu, Gordon J. Freeman, Vijay Kuchroo